Anti-oncogenic and pro-differentiation effects of clorgyline, a monoamine oxidase A inhibitor, on high grade prostate cancer cells.
BACKGROUND
Monoamine oxidase A (MAO-A), a mitochondrial enzyme that degrades monoamines including neurotransmitters, is highly expressed in basal cells of the normal human prostatic epithelium and in poorly differentiated (Gleason grades 4 and 5), aggressive prostate cancer (PCa). Clorgyline, an MAO-A inhibitor, induces secretory differentiation of normal prostate cells. We examined the effects of clorgyline on the transcriptional program of epithelial cells cultured from high grade PCa (E-CA).


METHODS
We systematically assessed gene expression changes induced by clorgyline in E-CA cells using high-density oligonucleotide microarrays. Genes differentially expressed in treated and control cells were identified by Significance Analysis of Microarrays. Expression of genes of interest was validated by quantitative real-time polymerase chain reaction.


RESULTS
The expression of 156 genes was significantly increased by clorgyline at all time points over the time course of 6 - 96 hr identified by Significance Analysis of Microarrays (SAM). The list is enriched with genes repressed in 7 of 12 oncogenic pathway signatures compiled from the literature. In addition, genes downregulated >or= 2-fold by clorgyline were significantly enriched with those upregulated by key oncogenes including beta-catenin and ERBB2, indicating an anti-oncogenic effect of clorgyline. Another striking effect of clorgyline was the induction of androgen receptor (AR) and classic AR target genes such as prostate-specific antigen together with other secretory epithelial cell-specific genes, suggesting that clorgyline promotes differentiation of cancer cells. Moreover, clorgyline downregulated EZH2, a critical component of the Polycomb Group (PcG) complex that represses the expression of differentiation-related genes. Indeed, many genes in the PcG repression signature that predicts PCa outcome were upregulated by clorgyline, suggesting that the differentiation-promoting effect of clorgyline may be mediated by its downregulation of EZH2.


CONCLUSIONS
Our results suggest that inhibitors of MAO-A, already in clinical use to treat depression, may have potential application as therapeutic PCa drugs by inhibiting oncogenic pathway activity and promoting differentiation.
Zhao
Hongjuan
H
Department of Urology, Stanford University School of Medicine, Stanford, California, USA. hongjuan@stanford.edu
Flamand
Vincent
V
Peehl
Donna M
DM
Differentiation. 2008 Sep;76(7):820-30
18248494
Cancer Res. 2004 Dec 15;64(24):8867-75
15604246
J Cell Biochem. 2006 Oct 1;99(2):333-44
16518832
Cancer Cell. 2004 Nov;6(5):517-27
15542435
Cancer Cell. 2002 Nov;2(5):349-50
12450788
Nat Med. 2004 Jan;10(1):33-9
14702632
Nat Rev Neurosci. 2006 Apr;7(4):295-309
16552415
Nucleic Acids Res. 2001 Jan 1;29(1):152-5
11125075
JAMA. 1999 May 5;281(17):1591-7
10235151
J Cell Sci. 2007 Oct 1;120(Pt 19):3327-35
17881494
Cancer Res. 2007 Nov 15;67(22):10657-63
18006806
Mod Pathol. 2004 Mar;17(3):292-306
14976540
Arch Immunol Ther Exp (Warsz). 2008 Mar-Apr;56(2):115-22
18373239
Endocr Relat Cancer. 2008 Mar;15(1):11-25
18310272
Differentiation. 2001 Oct;68(4-5):270-9
11776479
Endocr Rev. 2004 Apr;25(2):276-308
15082523
Endocr Rev. 2007 Dec;28(7):778-808
17940184
Methods Mol Med. 2003;81:41-57
12725113
Nature. 2006 Jan 19;439(7074):353-7
16273092
Genome Biol. 2002 Jun 14;3(7):RESEARCH0032
12184806
Cancer Cell. 2007 Nov;12(5):419-31
17996646
Int J Cancer. 2007 Feb 15;120(4):719-33
17163421
Cell. 2009 Mar 20;136(6):1122-35
19303854
Physiol Genomics. 2002 Sep 03;10(3):169-79
12209019
Br J Pharmacol. 2006 Jul;148(5):587-98
16702990
J Cell Physiol. 2006 May;207(2):428-36
16419040
Endocr Relat Cancer. 2003 Dec;10(4):537-60
14713266
J Neurochem. 2001 Feb;76(3):650-60
11158235
Differentiation. 2005 Dec;73(9-10):463-73
16351690
Neurochem Int. 1999 Jan;34(1):49-62
10100196
Dev Biol. 1999 Oct 15;214(2):331-41
10525338
Cell. 2006 Jun 2;125(5):971-86
16751105
Nucleic Acids Res. 2007;35(8):2767-76
17426117
Acta Crystallogr D Biol Crystallogr. 2004 Feb;60(Pt 2):317-9
14747710
J Neurochem. 1995 Feb;64(2):825-32
7830076
J Urol. 2008 Nov;180(5):2206-11
18804811
Cancer Metastasis Rev. 2001;20(3-4):207-23
12085963
J Urol. 1974 Jan;111(1):58-64
4813554
BMC Genomics. 2007 Apr 03;8:92
17407603
Prostate Cancer Prostatic Dis. 2005;8(2):119-26
15809669
Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21
11309499
Annu Rev Neurosci. 1999;22:197-217
10202537
Proc Natl Acad Sci U S A. 2006 Jul 18;103(29):10991-6
16829574
JAMA. 1999 Apr 21;281(15):1395-400
10217055
Am J Pathol. 2002 Jan;160(1):37-43
11786396
PLoS One. 2008 Mar 19;3(3):e1816
18350153